Curiteva

HardwareHuntsville, AL, USAFounded 2017· One of 1636 Hardware companies tracked by AMPulse

Develops proprietary fused strand deposition (FSD) 3D printers and bioactive nano-surface technology to manufacture FDA-cleared Trabecular PEEK spinal implants, enabling osseointegration and reducing patient recovery times.

CEO / Founder: Mike English
Team Size: 51-200
Stage: Active
Total Funding: $32.5M
Latest Round: Series A
Key Investors: Eastside Partners

Technology & Products

Key Products

Inspire Technology Platform for 3D printed PEEK spinal implants with bioactive nano-surface technology.

Technical position · AMPulse analysis

Patented FSD technology allows full control over implant porosity and structure, protected by FDA Master File and patents; HAFUSE surface technology is exclusive through partnership with Promimic, creating a regulatory and IP moat.

Differentiation

Value Proposition

Reduces spinal implant production costs by controlling the entire manufacturing process in-house, while offering a bioactive PEEK implant that enhances bone growth and reduces revision surgeries compared to traditional implants.

How They Differentiate

3x faster build speed and 30% lower cost-per-part for PEEK spinal implants compared to traditional manufacturing, with exclusive bioactive surface technology that competitors lack.

Market & Competition

Target Customers

Orthopedic surgeons and hospitals for spinal fusion procedures

Industry Verticals

Medical Devices; Orthopedics; Spine Surgery

Competitors

Innovasis; TranS1; 3D Systems

Growth & Milestones

Growth Metrics

60% growth in surgeries and 90% increase in surgeon customers over the past year; surpassed 10,000 levels successfully treated with Inspire implants.

Major Milestones

FDA 510(k) clearance for Inspire Porous PEEK Cervical Interbody System (2023); Acquisition of FossiLabs (2020); FDA nanotechnology designation for Inspire implants (2026); First US surgeries with Evonik-powered implants (April 2024); Expanded partnership with Promimic (May 2025)

Notable Customers

Surgeons and hospitals, with over 10,000 levels successfully treated.

https://curiteva.com

Recent coverage of Curiteva

Curiteva to double Inspire PEEK implant manufacturing capacity and construct 45,000 sq ft Innovation Center in Huntsvill...voxelmatters.comApr 9, 2026
Curiteva has received FDA nanotechnology designation for its Inspire 3D Printed Trabecular PEEK implants.ryortho.comJan 21, 2026

AM patents

AM-relevant patents linked to this company.

Patents: 10
Granted: 4
Families: 9

Leading domains: process (10), application (9), equipment (6)

Filings by year: 2024: 1 · 2023: 2 · 2022: 2 · 2021: 5

Additively manufactured porous polymer medical implants12263278 · US2023-10-12
SYSTEM AND METHOD OF MANUFACTURING A MEDICAL IMPLANT2022216312 · WO2022-10-13
ADDITIVELY MANUFACTURED POROUS POLYMER MEDICAL IMPLANTS04504492 · EP2025-02-12
ADDITIVELY MANUFACTURED POROUS POLYMER MEDICAL IMPLANTS2023196569 · WO2023-10-12
SYSTEM AND METHOD OF MANUFACTURING A MEDICAL IMPLANT20220327679 · US2022-10-13

Funding rounds

Series A$20.5M2020-12Source: Orthospinenews - December 2020
Equity$8M2019-11Source

Why this company matters

AMPulse analysis, not a company disclosure

Curiteva occupies a distinctive position in the orthopedic implant market by vertically integrating the design, printing, and surface treatment of PEEK spinal implants. While most competitors outsource manufacturing or rely on conventional machining and injection molding, Curiteva controls the entire production chain through its proprietary fused strand deposition (FSD) 3D printing process. This approach yields a 3x faster build speed and 30% lower cost-per-part compared to traditional methods, while enabling a porous trabecular structure that mimics cancellous bone.

The company's core technology stack includes custom FSD hardware, software, and slicing algorithms developed in-house. Its implants are coated with HAFUSE, a bioactive nano-surface technology licensed exclusively from Promimic that renders PEEK hydrophilic and osteoconductive. The combination of controlled porosity and surface bioactivity is designed to enhance osseointegration and reduce the need for revision surgeries. Curiteva holds an FDA nanotechnology designation for its Inspire implant line, creating a regulatory barrier that competitors without similar surface technology cannot easily replicate.

Target customers are orthopedic surgeons and hospitals performing spinal fusion procedures. Curiteva reports that over 10,000 levels have been successfully treated with its Inspire implants, with 60% growth in surgeries and a 90% increase in surgeon customers over the past year. Key milestones include FDA 510(k) clearance for the Inspire Porous PEEK Cervical Interbody System in 2023, the acquisition of FossiLabs in 2020, and an expanded partnership with Promimic in 2025. The company is backed by Eastside Partners with $32.5 million in total funding.

Curiteva's strategic moat rests on its vertically integrated FSD process, exclusive HAFUSE coating partnership, and FDA nanotechnology designation. Competitors such as Innovasis, TranS1, and 3D Systems offer PEEK or titanium implants but lack a comparable bioactive surface technology. The open question is whether Curiteva can scale its manufacturing capacity to meet growing surgeon demand and whether the HAFUSE coating's clinical benefits will translate into long-term outcomes data that justify premium pricing in a cost-sensitive hospital procurement environment.